{"DataElement":{"publicId":"2666513","version":"1","preferredName":"Sunitinib Malate Placebo Agent Received Dose","preferredDefinition":"the dose in milligrams received of sunitinib, a synthetic compound targeting tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2) and angiogenesis or placebo, an inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","longName":"SUNIT_PLC_RCVD_DS","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2666511","version":"1","preferredName":"Sunitinib Malate Placebo Agent Received","preferredDefinition":"information relating receiving sunitinib, a synthetic compound targeting tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2) and angiogenesis or placebo, an inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","longName":"SUN_PBO_AGT_RCVD","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2666509","version":"1","preferredName":"Sunitinib Malate Placebo Agent","preferredDefinition":"The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.:An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C26673:C753:C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sunitinib Malate","conceptCode":"C26673","definition":"The orally bioavailable malate salt of an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity.  Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35B4405A-F56A-4B74-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-07-20","modifiedBy":"ONEDATA","dateModified":"2007-07-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241679","version":"1","preferredName":"Received","preferredDefinition":"Received; taken, gotten, or acquired.","longName":"C25639","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Receive","conceptCode":"C25639","definition":"To take, accept, or get something offered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-2368-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-09","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-09","modifiedBy":"ONEDATA","dateModified":"2005-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"35B4405A-F578-4B74-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-07-20","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2432128","version":"1","preferredName":"Dose","preferredDefinition":"the dose in milligrams.","longName":"DOSE","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008560","version":"1","preferredName":"Therapy Doses","preferredDefinition":"quantities of therapy or treatment.","longName":"TX_DOSES","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B30C55B6-50B5-1219-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-30","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-30","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2432127","version":"1","preferredName":"Dose","preferredDefinition":"The amount of medicine taken, or radiation given, at one time.","longName":"C25488","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dose","conceptCode":"C25488","definition":"A quantity of an agent (such as substance or energy) administered, taken, or absorbed at one time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"061284D5-1977-0705-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-21","modifiedBy":"ONEDATA","dateModified":"2005-11-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"061284D5-1978-0705-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-21","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-11-21","modifiedBy":"ALAIS","dateModified":"2007-08-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811835","version":"1","longName":"Melanoma","context":"CTEP"},{"publicId":"2811871","version":"1","longName":"Colorectal","context":"CTEP"},{"publicId":"2811907","version":"1","longName":"Bladder","context":"CTEP"},{"publicId":"2811908","version":"1","longName":"Gynecologic","context":"CTEP"},{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"},{"publicId":"2811949","version":"1","longName":"Brain","context":"CTEP"},{"publicId":"2811950","version":"1","longName":"Multiple Myeloma","context":"CTEP"},{"publicId":"2811832","version":"1","longName":"Lung","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"},{"publicId":"2811962","version":"1","longName":"Response","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"10000001","version":"1","longName":"NSCLC Advanced","context":"CTEP"},{"publicId":"2811931","version":"1","longName":"NSCLC Stage I-III","context":"CTEP"}]},{"publicId":"2008608","version":"1","longName":"Phase","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811890","version":"1","longName":"Phase III","context":"CTEP"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Total dose of sunitinib/ plac","type":"Preferred Question Text","description":"Total dose of sunitinib/ placebo received during this reporting period","url":null,"context":"CTEP"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"35B448B1-6CB7-4D9B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-07-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-07-20","modifiedBy":"CAMPBELB","dateModified":"2008-07-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}